<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230923000906&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230923000906&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Sat, 23 Sep 2023 04:09:07 +0000</lastbuilddate>
<pubDate>Fri, 22 Sep 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Can we measurably improve the prediction of recurrent coronary artery disease events?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37738645/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230923000906&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 21;44(36):3466-3468. doi: 10.1093/eurheartj/ehad464.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37738645/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230923000906&v=2.17.9.post6+86293ac">37738645</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad464>10.1093/eurheartj/ehad464</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37738645</guid>
<pubDate>Fri, 22 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>William S Weintraub</dc:creator>
<dc:creator>William E Boden</dc:creator>
<dc:date>2023-09-22</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Can we measurably improve the prediction of recurrent coronary artery disease events?</dc:title>
<dc:identifier>pmid:37738645</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad464</dc:identifier>
</item>
<item>
<title>Challenges and opportunities in prognostication: focus on ischaemic heart disease and atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37738644/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230923000906&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 21;44(36):3391-3394. doi: 10.1093/eurheartj/ehad614.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37738644/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230923000906&v=2.17.9.post6+86293ac">37738644</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad614>10.1093/eurheartj/ehad614</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37738644</guid>
<pubDate>Fri, 22 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2023-09-22</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Challenges and opportunities in prognostication: focus on ischaemic heart disease and atrial fibrillation</dc:title>
<dc:identifier>pmid:37738644</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad614</dc:identifier>
</item>
<item>
<title>Correction to: 2023 ESC Guidelines for the management of endocarditis: Developed by the task force on the management of endocarditis of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Nuclear Medicine (EANM)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37738322/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230923000906&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 20:ehad625. doi: 10.1093/eurheartj/ehad625. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37738322/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230923000906&v=2.17.9.post6+86293ac">37738322</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad625>10.1093/eurheartj/ehad625</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37738322</guid>
<pubDate>Fri, 22 Sep 2023 06:00:00 -0400</pubDate>
<dc:date>2023-09-22</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: 2023 ESC Guidelines for the management of endocarditis: Developed by the task force on the management of endocarditis of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Nuclear Medicine (EANM)</dc:title>
<dc:identifier>pmid:37738322</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad625</dc:identifier>
</item>
<item>
<title>Birth weight influences cardiac structure, function, and disease risk: evidence of a causal association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37738114/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230923000906&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: The results of this study support a causal role of low birth weight in cardiovascular disease, even after accounting for the influence of the intrauterine environment. This suggests that individuals with a low birth weight may benefit from early targeted cardiovascular disease prevention strategies, independent of whether this was linked to an adverse intrauterine environment during gestation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 20:ehad631. doi: 10.1093/eurheartj/ehad631. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Low birth weight is a common pregnancy complication, which has been associated with higher risk of cardiometabolic disease in later life. Prior Mendelian randomization (MR) studies exploring this question do not distinguish the mechanistic contributions of variants that directly influence birth weight through the foetal genome (direct foetal effects), vs. variants influencing birth weight indirectly by causing an adverse intrauterine environment (indirect maternal effects). In this study, MR was used to assess whether birth weight, independent of intrauterine influences, is associated with cardiovascular disease risk and measures of adverse cardiac structure and function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Uncorrelated (r2 &lt; .001), genome-wide significant (P &lt; 5 × 10-8) single nucleotide polymorphisms were extracted from genome-wide association studies summary statistics for birth weight overall, and after isolating direct foetal effects only. Inverse-variance weighted MR was utilized for analyses on outcomes of atrial fibrillation, coronary artery disease, heart failure, ischaemic stroke, and 16 measures of cardiac structure and function. Multiple comparisons were accounted for by Benjamini-Hochberg correction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Lower genetically-predicted birth weight, isolating direct foetal effects only, was associated with an increased risk of coronary artery disease (odds ratio 1.21, 95% confidence interval 1.06-1.37; P = .031), smaller chamber volumes, and lower stroke volume, but higher contractility.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The results of this study support a causal role of low birth weight in cardiovascular disease, even after accounting for the influence of the intrauterine environment. This suggests that individuals with a low birth weight may benefit from early targeted cardiovascular disease prevention strategies, independent of whether this was linked to an adverse intrauterine environment during gestation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37738114/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230923000906&v=2.17.9.post6+86293ac">37738114</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad631>10.1093/eurheartj/ehad631</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37738114</guid>
<pubDate>Fri, 22 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Maddalena Ardissino</dc:creator>
<dc:creator>Alec P Morley</dc:creator>
<dc:creator>Eric A W Slob</dc:creator>
<dc:creator>Art Schuermans</dc:creator>
<dc:creator>Bilal Rayes</dc:creator>
<dc:creator>Zahra Raisi-Estabragh</dc:creator>
<dc:creator>Antonio de Marvao</dc:creator>
<dc:creator>Stephen Burgess</dc:creator>
<dc:creator>Tormod Rogne</dc:creator>
<dc:creator>Michael C Honigberg</dc:creator>
<dc:creator>Fu Siong Ng</dc:creator>
<dc:date>2023-09-22</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Birth weight influences cardiac structure, function, and disease risk: evidence of a causal association</dc:title>
<dc:identifier>pmid:37738114</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad631</dc:identifier>
</item>
<item>
<title>PPP1R12C Promotes Atrial Hypocontractility in Atrial Fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37737016/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230923000906&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Patients with AF exhibit increased levels of PPP1R12C protein compared with controls. PPP1R12C overexpression in mice increases PP1c targeting to MLC2a and causes MLC2a dephosphorylation, which reduces atrial contractility and increases AF inducibility. These findings suggest that PP1 regulation of sarcomere function at MLC2a is a key determinant of atrial contractility in AF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Sep 22. doi: 10.1161/CIRCRESAHA.123.322516. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Atrial fibrillation (AF)-the most common sustained cardiac arrhythmia-increases thromboembolic stroke risk 5-fold. Although atrial hypocontractility contributes to stroke risk in AF, the molecular mechanisms reducing myofilament contractile function remain unknown. We tested the hypothesis that increased expression of PPP1R12C (protein phosphatase 1 regulatory subunit 12C)-the PP1 (protein phosphatase 1) regulatory subunit targeting MLC2a (atrial myosin light chain 2)-causes hypophosphorylation of MLC2a and results in atrial hypocontractility.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Right atrial appendage tissues were isolated from human patients with AF versus sinus rhythm controls. Western blots, coimmunoprecipitation, and phosphorylation studies were performed to examine how the PP1c (PP1 catalytic subunit)-PPP1R12C interaction causes MLC2a dephosphorylation. In vitro studies of pharmacological MRCK (myotonic dystrophy kinase-related Cdc42-binding kinase) inhibitor (BDP5290) in atrial HL-1 cells were performed to evaluate PP1 holoenzyme activity on MLC2a. Cardiac-specific lentiviral PPP1R12C overexpression was performed in mice to evaluate atrial remodeling with atrial cell shortening assays, echocardiography, and AF inducibility with electrophysiology studies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In human patients with AF, PPP1R12C expression was increased 2-fold versus sinus rhythm controls (<i>P</i>=2.0×10<sup>-</sup><sup>2</sup>; n=12 and 12 in each group) with >;40% reduction in MLC2a phosphorylation (<i>P</i>=1.4×10<sup>-</sup><sup>6</sup>; n=12 and 12 in each group). PPP1R12C-PP1c binding and PPP1R12C-MLC2a binding were significantly increased in AF (<i>P</i>=2.9×10<sup>-2</sup> and 6.7×10<sup>-3</sup>, respectively; n=8 and 8 in each group). In vitro studies utilizing drug BDP5290, which inhibits T560-PPP1R12C phosphorylation, demonstrated increased PPP1R12C binding with both PP1c and MLC2a and dephosphorylation of MLC2a. Mice treated with lentiviral PPP1R12C vector demonstrated a 150% increase in left atrial size versus controls (<i>P</i>=5.0×10<sup>-</sup><sup>6</sup>; n=12, 8, and 12), with reduced atrial strain and atrial ejection fraction. Pacing-induced AF in mice treated with lentiviral PPP1R12C vector was significantly higher than in controls (<i>P</i>=1.8×10<sup>-2</sup> and 4.1×10<sup>-2</sup>, respectively; n=6, 6, and 5).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients with AF exhibit increased levels of PPP1R12C protein compared with controls. PPP1R12C overexpression in mice increases PP1c targeting to MLC2a and causes MLC2a dephosphorylation, which reduces atrial contractility and increases AF inducibility. These findings suggest that PP1 regulation of sarcomere function at MLC2a is a key determinant of atrial contractility in AF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37737016/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230923000906&v=2.17.9.post6+86293ac">37737016</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322516>10.1161/CIRCRESAHA.123.322516</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37737016</guid>
<pubDate>Fri, 22 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Srikanth Perike</dc:creator>
<dc:creator>Francisco J Gonzalez-Gonzalez</dc:creator>
<dc:creator>Issam Abu-Taha</dc:creator>
<dc:creator>Frederick W Damen</dc:creator>
<dc:creator>Laurin M Hanft</dc:creator>
<dc:creator>Ken S Lizama</dc:creator>
<dc:creator>Anahita Aboonabi</dc:creator>
<dc:creator>Andrielle E Capote</dc:creator>
<dc:creator>Yuriana Aguilar-Sanchez</dc:creator>
<dc:creator>Benjamin Levin</dc:creator>
<dc:creator>Zhenbo Han</dc:creator>
<dc:creator>Arvind Sridhar</dc:creator>
<dc:creator>Jacob Grand</dc:creator>
<dc:creator>Jody Martin</dc:creator>
<dc:creator>Joseph G Akar</dc:creator>
<dc:creator>Chad M Warren</dc:creator>
<dc:creator>R John Solaro</dc:creator>
<dc:creator>Sang-Ging Ong</dc:creator>
<dc:creator>Dawood Darbar</dc:creator>
<dc:creator>Kerry S McDonald</dc:creator>
<dc:creator>Craig J Goergen</dc:creator>
<dc:creator>Beata M Wolska</dc:creator>
<dc:creator>Dobromir Dobrev</dc:creator>
<dc:creator>Xander H T Wehrens</dc:creator>
<dc:creator>Mark D McCauley</dc:creator>
<dc:date>2023-09-22</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>PPP1R12C Promotes Atrial Hypocontractility in Atrial Fibrillation</dc:title>
<dc:identifier>pmid:37737016</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322516</dc:identifier>
</item>
<item>
<title>Implementation of Global Hearts Hypertension Control Programs in 32 Low- and Middle-Income Countries: JACC International</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37734459/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230923000906&amp;v=2.17.9.post6+86293ac
      <description>In 2017, the World Health Organization (WHO) and Resolve to Save Lives partnered with country governments and other stakeholders to design, test, and scale up the WHO HEARTS hypertension services package in 32 low- and middle-income countries. Facility-based HEARTS performance indicators included number of patients enrolled, number treated and with blood pressure controlled, number who missed a scheduled follow-up visit, and number lost to follow-up. By 2022, HEARTS hypertension control programs...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 19:S0735-1097(23)06633-0. doi: 10.1016/j.jacc.2023.08.043. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In 2017, the World Health Organization (WHO) and Resolve to Save Lives partnered with country governments and other stakeholders to design, test, and scale up the WHO HEARTS hypertension services package in 32 low- and middle-income countries. Facility-based HEARTS performance indicators included number of patients enrolled, number treated and with blood pressure controlled, number who missed a scheduled follow-up visit, and number lost to follow-up. By 2022, HEARTS hypertension control programs treated 12.2 million patients in 165,000 primary care facilities. Hypertension control was 38% (median 48%; range 5%-86%). In 4 HEARTS countries using the same digital health information system, facility-based control improved from 18% at baseline to 46% in 48 months. At the population level, median estimated population-based hypertension control was 11.0% of all hypertension patients (range 2.0%-34.7%). The Global Hearts experience of implementing WHO HEARTS demonstrates the feasibility of controlling hypertension in low- and middle-income country primary care settings.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37734459/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230923000906&v=2.17.9.post6+86293ac">37734459</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.043>10.1016/j.jacc.2023.08.043</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37734459</guid>
<pubDate>Thu, 21 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Andrew E Moran</dc:creator>
<dc:creator>Reena Gupta</dc:creator>
<dc:creator>Global Hearts Initiative Collaborators</dc:creator>
<dc:date>2023-09-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Implementation of Global Hearts Hypertension Control Programs in 32 Low- and Middle-Income Countries: JACC International</dc:title>
<dc:identifier>pmid:37734459</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.043</dc:identifier>
</item>
<item>
<title>Mpox infection protects against re-challenge in rhesus macaques</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37734373/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230923000906&amp;v=2.17.9.post6+86293ac
      <description>The mpox outbreak of 2022-2023 involved rapid global spread in men who have sex with men. We infected 18 rhesus macaques with mpox by the intravenous, intradermal, and intrarectal routes and observed robust antibody and T cell responses following all three routes of infection. Numerous skin lesions and high plasma viral loads were observed following intravenous and intradermal infection. Skin lesions peaked on day 10 and resolved by day 28 following infection. On day 28, we re-challenged all...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 13:S0092-8674(23)00911-X. doi: 10.1016/j.cell.2023.08.023. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The mpox outbreak of 2022-2023 involved rapid global spread in men who have sex with men. We infected 18 rhesus macaques with mpox by the intravenous, intradermal, and intrarectal routes and observed robust antibody and T cell responses following all three routes of infection. Numerous skin lesions and high plasma viral loads were observed following intravenous and intradermal infection. Skin lesions peaked on day 10 and resolved by day 28 following infection. On day 28, we re-challenged all convalescent and 3 naive animals with mpox. All convalescent animals were protected against re-challenge. Transcriptomic studies showed upregulation of innate and inflammatory responses and downregulation of collagen formation and extracellular matrix organization following challenge, as well as rapid activation of T cell and plasma cell responses following re-challenge. These data suggest key mechanistic insights into mpox pathogenesis and immunity. This macaque model should prove useful for evaluating mpox vaccines and therapeutics.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37734373/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230923000906&v=2.17.9.post6+86293ac">37734373</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.023>10.1016/j.cell.2023.08.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37734373</guid>
<pubDate>Thu, 21 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Malika Aid</dc:creator>
<dc:creator>Michaela Sciacca</dc:creator>
<dc:creator>Katherine McMahan</dc:creator>
<dc:creator>David Hope</dc:creator>
<dc:creator>Jinyan Liu</dc:creator>
<dc:creator>Catherine Jacob-Dolan</dc:creator>
<dc:creator>Olivia Powers</dc:creator>
<dc:creator>Julia Barrett</dc:creator>
<dc:creator>Cindy Wu</dc:creator>
<dc:creator>Audrey Mutoni</dc:creator>
<dc:creator>Tetyana Murdza</dc:creator>
<dc:creator>Hannah Richter</dc:creator>
<dc:creator>Jason Velasco</dc:creator>
<dc:creator>Elyse Teow</dc:creator>
<dc:creator>Mona Boursiquot</dc:creator>
<dc:creator>Anthony Cook</dc:creator>
<dc:creator>Tatyana Orekov</dc:creator>
<dc:creator>Melissa Hamilton</dc:creator>
<dc:creator>Laurent Pessaint</dc:creator>
<dc:creator>Alaina Ryan</dc:creator>
<dc:creator>Tammy Hayes</dc:creator>
<dc:creator>Amanda J Martinot</dc:creator>
<dc:creator>Michael S Seaman</dc:creator>
<dc:creator>Mark G Lewis</dc:creator>
<dc:creator>Hanne Andersen</dc:creator>
<dc:creator>Dan H Barouch</dc:creator>
<dc:date>2023-09-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Mpox infection protects against re-challenge in rhesus macaques</dc:title>
<dc:identifier>pmid:37734373</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.023</dc:identifier>
</item>
<item>
<title>Host traits shape virome composition and virus transmission in wild small mammals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37734372/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230923000906&amp;v=2.17.9.post6+86293ac
      <description>Bats, rodents, and shrews are the most important animal sources of human infectious diseases. However, the evolution and transmission of viruses among them remain largely unexplored. Through the meta-transcriptomic sequencing of internal organ and fecal samples from 2,443 wild bats, rodents, and shrews sampled from four Chinese habitats, we identified 669 viruses, including 534 novel viruses, thereby greatly expanding the mammalian virome. Our analysis revealed high levels of phylogenetic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 14:S0092-8674(23)00916-9. doi: 10.1016/j.cell.2023.08.029. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Bats, rodents, and shrews are the most important animal sources of human infectious diseases. However, the evolution and transmission of viruses among them remain largely unexplored. Through the meta-transcriptomic sequencing of internal organ and fecal samples from 2,443 wild bats, rodents, and shrews sampled from four Chinese habitats, we identified 669 viruses, including 534 novel viruses, thereby greatly expanding the mammalian virome. Our analysis revealed high levels of phylogenetic diversity, identified cross-species virus transmission events, elucidated virus origins, and identified cases of invertebrate viruses in mammalian hosts. Host order and sample size were the most important factors impacting virome composition and patterns of virus spillover. Shrews harbored a high richness of viruses, including many invertebrate-associated viruses with multi-organ distributions, whereas rodents carried viruses with a greater capacity for host jumping. These data highlight the remarkable diversity of mammalian viruses in local habitats and their ability to emerge in new hosts.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37734372/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230923000906&v=2.17.9.post6+86293ac">37734372</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.029>10.1016/j.cell.2023.08.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37734372</guid>
<pubDate>Thu, 21 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Yan-Mei Chen</dc:creator>
<dc:creator>Shu-Jian Hu</dc:creator>
<dc:creator>Xian-Dan Lin</dc:creator>
<dc:creator>Jun-Hua Tian</dc:creator>
<dc:creator>Jia-Xin Lv</dc:creator>
<dc:creator>Miao-Ruo Wang</dc:creator>
<dc:creator>Xiu-Qi Luo</dc:creator>
<dc:creator>Yuan-Yuan Pei</dc:creator>
<dc:creator>Rui-Xue Hu</dc:creator>
<dc:creator>Zhi-Gang Song</dc:creator>
<dc:creator>Edward C Holmes</dc:creator>
<dc:creator>Yong-Zhen Zhang</dc:creator>
<dc:date>2023-09-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Host traits shape virome composition and virus transmission in wild small mammals</dc:title>
<dc:identifier>pmid:37734372</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.029</dc:identifier>
</item>
<item>
<title>Combined Treatment of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Endothelial Cells Regenerate the Infarcted Heart in Mice and Non-Human Primates</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37732466/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230923000906&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: These results demonstrate the synergistic effect of combining iPSC-derived ECs and CMs for therapy in the postmyocardial infarction heart, enabling a promising strategy toward clinical translation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 21. doi: 10.1161/CIRCULATIONAHA.122.061736. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Remuscularization of the mammalian heart can be achieved after cell transplantation of human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (CMs). However, several hurdles remain before implementation into clinical practice. Poor survival of the implanted cells is related to insufficient vascularization, and the potential for fatal arrhythmogenesis is associated with the fetal cell-like nature of immature CMs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We generated 3 lines of hiPSC-derived endothelial cells (ECs) and hiPSC-CMs from 3 independent donors and tested hiPSC-CM sarcomeric length, gap junction protein, and calcium-handling ability in coculture with ECs. Next, we examined the therapeutic effect of the cotransplantation of hiPSC-ECs and hiPSC-CMs in NOD-SCID mice undergoing myocardial infarction (n≥4). Cardiac function was assessed by echocardiography, whereas arrhythmic events were recorded using 3-lead ECGs. We further used healthy non-human primates (n=4) with cell injection to study the cell engraftment, maturation, and integration of transplanted hiPSC-CMs, alone or along with hiPSC-ECs, by histological analysis. Last, we tested the cell therapy in ischemic reperfusion injury in non-human primates (n=4, 3, and 4 for EC+CM, CM, and control, respectively). Cardiac function was evaluated by echocardiography and cardiac MRI, whereas arrhythmic events were monitored by telemetric ECG recorders. Cell engraftment, angiogenesis, and host-graft integration of human grafts were also investigated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We demonstrated that human iPSC-ECs promote the maturity and function of hiPSC-CMs in vitro and in vivo. When cocultured with ECs, CMs showed more mature phenotypes in cellular structure and function. In the mouse model, cotransplantation augmented the EC-accompanied vascularization in the grafts, promoted the maturity of CMs at the infarct area, and improved cardiac function after myocardial infarction. Furthermore, in non-human primates, transplantation of ECs and CMs significantly enhanced graft size and vasculature and improved cardiac function after ischemic reperfusion.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These results demonstrate the synergistic effect of combining iPSC-derived ECs and CMs for therapy in the postmyocardial infarction heart, enabling a promising strategy toward clinical translation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37732466/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230923000906&v=2.17.9.post6+86293ac">37732466</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.061736>10.1161/CIRCULATIONAHA.122.061736</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37732466</guid>
<pubDate>Thu, 21 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Yu-Che Cheng</dc:creator>
<dc:creator>Marvin L Hsieh</dc:creator>
<dc:creator>Chen-Ju Lin</dc:creator>
<dc:creator>Cindy M C Chang</dc:creator>
<dc:creator>Ching-Ying Huang</dc:creator>
<dc:creator>Riley Puntney</dc:creator>
<dc:creator>Amy Wu Moy</dc:creator>
<dc:creator>Chien-Yu Ting</dc:creator>
<dc:creator>Darien Zhing Herr Chan</dc:creator>
<dc:creator>Martin W Nicholson</dc:creator>
<dc:creator>Po-Ju Lin</dc:creator>
<dc:creator>Hung-Chih Chen</dc:creator>
<dc:creator>Gina C Kim</dc:creator>
<dc:creator>Jianhua Zhang</dc:creator>
<dc:creator>Jennifer Coonen</dc:creator>
<dc:creator>Puja Basu</dc:creator>
<dc:creator>Heather A Simmons</dc:creator>
<dc:creator>Yen-Wen Liu</dc:creator>
<dc:creator>Timothy A Hacker</dc:creator>
<dc:creator>Timothy J Kamp</dc:creator>
<dc:creator>Patrick C H Hsieh</dc:creator>
<dc:date>2023-09-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Combined Treatment of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Endothelial Cells Regenerate the Infarcted Heart in Mice and Non-Human Primates</dc:title>
<dc:identifier>pmid:37732466</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.061736</dc:identifier>
</item>
<item>
<title>Oral Anticoagulation Use and Left Atrial Appendage Occlusion in LAAOS III</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37732457/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230923000906&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: The benefit of LAA occlusion was consistent whether patients were receiving OACs or not. LAA occlusion provides thromboembolism reduction in patients independent of OAC use.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 21. doi: 10.1161/CIRCULATIONAHA.122.060315. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: LAAOS III (Left Atrial Appendage Occlusion Study III) showed that left atrial appendage (LAA) occlusion reduces the risk of ischemic stroke or systemic embolism in patients with atrial fibrillation undergoing cardiac surgery. This article examines the effect of LAA occlusion on stroke reduction according to variation in the use of oral anticoagulants (OACs).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Information regarding OAC use was collected at every follow-up visit. Adjusted proportional hazards modeling, including using landmarks of hospital discharge, 1 and 2 years after randomization, evaluated the effect of LAA occlusion on the risk of ischemic stroke or systemic embolism, according to OAC use. Adjusted proportional hazard modeling, with OAC use as a time-dependent covariate, was also performed to assess the effect of LAA occlusion, according to OAC use throughout the study.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At hospital discharge, 3027 patients (63.5%) were receiving a vitamin K antagonist, and 879 (18.5%) were receiving a non-vitamin K antagonist oral anticoagulant (direct OAC), with no difference in OAC use between treatment arms. There were 2887 (60.5%) patients who received OACs at all follow-up visits, 1401 (29.4%) who received OAC at some visits, and 472 (9.9%) who never received OACs. The effect of LAA occlusion on the risk of ischemic stroke or systemic embolism was consistent after discharge across all 3 groups: hazard ratios of 0.70 (95% CI, 0.51-0.96), 0.63 (95% CI, 0.43-0.94), and 0.76 (95% CI, 0.32-1.79), respectively. An adjusted proportional hazards model with OAC use as a time-dependent covariate showed that the reduction in stroke or systemic embolism with LAA occlusion was similar whether patients were receiving OACs or not.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The benefit of LAA occlusion was consistent whether patients were receiving OACs or not. LAA occlusion provides thromboembolism reduction in patients independent of OAC use.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37732457/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230923000906&v=2.17.9.post6+86293ac">37732457</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.060315>10.1161/CIRCULATIONAHA.122.060315</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37732457</guid>
<pubDate>Thu, 21 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Stuart J Connolly</dc:creator>
<dc:creator>Jeff S Healey</dc:creator>
<dc:creator>Emilie P Belley-Cote</dc:creator>
<dc:creator>Kumar Balasubramanian</dc:creator>
<dc:creator>Domenico Paparella</dc:creator>
<dc:creator>Katheryn Brady</dc:creator>
<dc:creator>Wilko Reents</dc:creator>
<dc:creator>Bernhard C Danner</dc:creator>
<dc:creator>P J Devereaux</dc:creator>
<dc:creator>Mukul Sharma</dc:creator>
<dc:creator>Chinthanie Ramasundarahettige</dc:creator>
<dc:creator>Salim Yusuf</dc:creator>
<dc:creator>Richard P Whitlock</dc:creator>
<dc:date>2023-09-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Oral Anticoagulation Use and Left Atrial Appendage Occlusion in LAAOS III</dc:title>
<dc:identifier>pmid:37732457</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.060315</dc:identifier>
</item>
<item>
<title>Existing Nongated CT Coronary Calcium Predicts Operative Risk in Patients Undergoing Noncardiac Surgeries (ENCORES)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37732454/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230923000906&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Prevalence and severity of coronary calcium obtained from existing nongated chest CT imaging improve preoperative clinical risk stratification before nongated surgery.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 21. doi: 10.1161/CIRCULATIONAHA.123.064398. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Preoperative cardiovascular risk stratification before noncardiac surgery is a common clinical challenge. Coronary artery calcium scores from ECG-gated chest computed tomography (CT) imaging are associated with perioperative events. At the time of preoperative evaluation, many patients will not have had ECG-gated CT imaging, but will have had nongated chest CT studies performed for a variety of noncardiac indications. We evaluated relationships between coronary calcium severity estimated from previous nongated chest CT imaging and perioperative major clinical events (MCE) after noncardiac surgery.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We retrospectively identified consecutive adults age ≥45 years who underwent in-hospital, major nongated surgery from 2016 to 2020 at a large academic health system composed of 4 acute care centers. All patients had nongated (contrast or noncontrast) chest CT imaging performed within 1 year before surgery. Coronary calcium in each vessel was retrospectively graded from absent to severe using a 0 to 3 scale (absent, mild, moderate, severe) by physicians blinded to clinical data. The estimated coronary calcium burden (ECCB) was computed as the sum of scores for each coronary artery (0 to 9 scale). A Revised Cardiac Risk Index was calculated for each patient. Perioperative MCE was defined as all-cause death or myocardial infarction within 30 days of surgery.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 2554 patients (median age, 68 years; 49.7% women; median Revised Cardiac Risk Index, 1) were included. The median time interval from nongated chest CT imaging to nongated surgery was 15 days (interquartile range, 3-106 days). The median ECCB was 1 (interquartile range, 0-3). Perioperative MCE occurred in 136 (5.2%) patients. Higher ECCB values were associated with stepwise increases in perioperative MCE (0: 2.9%, 1-2: 3.7%, 3-5: 8.0%; 6-9: 12.6%, <i>P</i>&lt;0.001). Addition of ECCB to a model with the Revised Cardiac Risk Index improved the C-statistic for MCE (from 0.675 to 0.712, <i>P</i>=0.018), with a net reclassification improvement of 0.428 (95% CI, 0.254-0.601, <i>P</i>&lt;0.0001). An ECCB ≥3 was associated with 2-fold higher adjusted odds of MCE versus an ECCB &lt;3 (adjusted odds ratio, 2.11 [95% CI, 1.42-3.12]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Prevalence and severity of coronary calcium obtained from existing nongated chest CT imaging improve preoperative clinical risk stratification before nongated surgery.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37732454/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230923000906&v=2.17.9.post6+86293ac">37732454</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064398>10.1161/CIRCULATIONAHA.123.064398</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37732454</guid>
<pubDate>Thu, 21 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Daniel Y Choi</dc:creator>
<dc:creator>Dena Hayes</dc:creator>
<dc:creator>Samuel D Maidman</dc:creator>
<dc:creator>Nehal Dhaduk</dc:creator>
<dc:creator>Jill E Jacobs</dc:creator>
<dc:creator>Anna Shmukler</dc:creator>
<dc:creator>Jeffrey S Berger</dc:creator>
<dc:creator>Germaine Cuff</dc:creator>
<dc:creator>David Rehe</dc:creator>
<dc:creator>Mitchell Lee</dc:creator>
<dc:creator>Robert Donnino</dc:creator>
<dc:creator>Nathaniel R Smilowitz</dc:creator>
<dc:date>2023-09-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Existing Nongated CT Coronary Calcium Predicts Operative Risk in Patients Undergoing Noncardiac Surgeries (ENCORES)</dc:title>
<dc:identifier>pmid:37732454</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064398</dc:identifier>
</item>
<item>
<title>Cardiovascular Imaging in Contemporary Cardio-Oncology: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37732422/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230923000906&amp;v=2.17.9.post6+86293ac
      <description>Advances in cancer therapeutics have led to dramatic improvements in survival, now inclusive of nearly 20 million patients and rising. However, cardiovascular toxicities associated with specific cancer therapeutics adversely affect the outcomes of patients with cancer. Advances in cardiovascular imaging have solidified the critical role for robust methods for detecting, monitoring, and prognosticating cardiac risk among patients with cancer. However, decentralized evaluations have led to a lack...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 21. doi: 10.1161/CIR.0000000000001174. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Advances in cancer therapeutics have led to dramatic improvements in survival, now inclusive of nearly 20 million patients and rising. However, cardiovascular toxicities associated with specific cancer therapeutics adversely affect the outcomes of patients with cancer. Advances in cardiovascular imaging have solidified the critical role for robust methods for detecting, monitoring, and prognosticating cardiac risk among patients with cancer. However, decentralized evaluations have led to a lack of consensus on the optimal uses of imaging in contemporary cancer treatment (eg, immunotherapy, targeted, or biological therapy) settings. Similarly, available isolated preclinical and clinical studies have provided incomplete insights into the effectiveness of multiple modalities for cardiovascular imaging in cancer care. The aims of this scientific statement are to define the current state of evidence for cardiovascular imaging in the cancer treatment and survivorship settings and to propose novel methodological approaches to inform the optimal application of cardiovascular imaging in future clinical trials and registries. We also propose an evidence-based integrated approach to the use of cardiovascular imaging in routine clinical settings. This scientific statement summarizes and clarifies available evidence while providing guidance on the optimal uses of multimodality cardiovascular imaging in the era of emerging anticancer therapies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37732422/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230923000906&v=2.17.9.post6+86293ac">37732422</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001174>10.1161/CIR.0000000000001174</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37732422</guid>
<pubDate>Thu, 21 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Daniel Addison</dc:creator>
<dc:creator>Tomas G Neilan</dc:creator>
<dc:creator>Ana Barac</dc:creator>
<dc:creator>Marielle Scherrer-Crosbie</dc:creator>
<dc:creator>Tochi M Okwuosa</dc:creator>
<dc:creator>Juan C Plana</dc:creator>
<dc:creator>Kerryn W Reding</dc:creator>
<dc:creator>Viviany R Taqueti</dc:creator>
<dc:creator>Eric H Yang</dc:creator>
<dc:creator>Vlad G Zaha</dc:creator>
<dc:creator>American Heart Association Council on Cardiovascular Radiology and Intervention; Cardio-Oncology Committee of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine; and Council on Cardiovascular and Stroke Nursing</dc:creator>
<dc:date>2023-09-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiovascular Imaging in Contemporary Cardio-Oncology: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:37732422</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001174</dc:identifier>
</item>
<item>
<title>CHIP in HF: prognostic role and cell-intrinsic effects</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37730906/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230923000906&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Sep 20. doi: 10.1038/s41569-023-00942-7. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37730906/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230923000906&v=2.17.9.post6+86293ac">37730906</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00942-7>10.1038/s41569-023-00942-7</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37730906</guid>
<pubDate>Thu, 21 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2023-09-21</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>CHIP in HF: prognostic role and cell-intrinsic effects</dc:title>
<dc:identifier>pmid:37730906</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00942-7</dc:identifier>
</item>
<item>
<title>Reply: Acetazolamide in Acute Decompensated Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37730297/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230923000906&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 26;82(13):e113. doi: 10.1016/j.jacc.2023.07.016.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37730297/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230923000906&v=2.17.9.post6+86293ac">37730297</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.016>10.1016/j.jacc.2023.07.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37730297</guid>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Frederik H Verbrugge</dc:creator>
<dc:creator>Pieter Martens</dc:creator>
<dc:creator>Wilfried Mullens</dc:creator>
<dc:date>2023-09-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Acetazolamide in Acute Decompensated Heart Failure</dc:title>
<dc:identifier>pmid:37730297</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.016</dc:identifier>
</item>
<item>
<title>Acetazolamide in Acute Decompensated Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37730296/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230923000906&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 26;82(13):e111. doi: 10.1016/j.jacc.2023.06.048.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37730296/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230923000906&v=2.17.9.post6+86293ac">37730296</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.048>10.1016/j.jacc.2023.06.048</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37730296</guid>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Ramdas G Pai</dc:creator>
<dc:date>2023-09-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Acetazolamide in Acute Decompensated Heart Failure</dc:title>
<dc:identifier>pmid:37730296</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.048</dc:identifier>
</item>
<item>
<title>Impact of Socioeconomic Background on Cardiovascular Health Promotion in Early Childhood</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37730295/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230923000906&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 26;82(13):1377-1379. doi: 10.1016/j.jacc.2023.07.014.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37730295/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230923000906&v=2.17.9.post6+86293ac">37730295</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.014>10.1016/j.jacc.2023.07.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37730295</guid>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Amaya de Cos-Gandoy</dc:creator>
<dc:creator>Gloria Santos-Beneit</dc:creator>
<dc:creator>Patricia Bodega</dc:creator>
<dc:creator>Jorge Baxter</dc:creator>
<dc:creator>Raquel Diaz-Munoz</dc:creator>
<dc:creator>Christopher A Hill</dc:creator>
<dc:creator>Isabel Carvajal</dc:creator>
<dc:creator>Carlos Peyra</dc:creator>
<dc:creator>Rodrigo Fernandez-Jimenez</dc:creator>
<dc:creator>Valentin Fuster</dc:creator>
<dc:date>2023-09-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Impact of Socioeconomic Background on Cardiovascular Health Promotion in Early Childhood</dc:title>
<dc:identifier>pmid:37730295</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.014</dc:identifier>
</item>
<item>
<title>Ethics in Cardiovascular Care: A Call to Action</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37730294/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230923000906&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 26;82(13):1373-1376. doi: 10.1016/j.jacc.2023.08.004.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37730294/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230923000906&v=2.17.9.post6+86293ac">37730294</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.004>10.1016/j.jacc.2023.08.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37730294</guid>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Jorge R Alegria</dc:creator>
<dc:creator>B Hadley Wilson</dc:creator>
<dc:creator>R Scott Wright</dc:creator>
<dc:date>2023-09-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Ethics in Cardiovascular Care: A Call to Action</dc:title>
<dc:identifier>pmid:37730294</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.004</dc:identifier>
</item>
<item>
<title>Generalized Pairwise Comparisons to Assess Treatment Effects: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37730293/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230923000906&amp;v=2.17.9.post6+86293ac
      <description>A time-to-first-event composite endpoint analysis has well-known shortcomings in evaluating a treatment effect in cardiovascular clinical trials. It does not fully describe the clinical benefit of therapy because the severity of the events, events repeated over time, and clinically relevant nonsurvival outcomes cannot be considered. The generalized pairwise comparisons (GPC) method adds flexibility in defining the primary endpoint by including any number and type of outcomes that best capture...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 26;82(13):1360-1372. doi: 10.1016/j.jacc.2023.06.047.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">A time-to-first-event composite endpoint analysis has well-known shortcomings in evaluating a treatment effect in cardiovascular clinical trials. It does not fully describe the clinical benefit of therapy because the severity of the events, events repeated over time, and clinically relevant nonsurvival outcomes cannot be considered. The generalized pairwise comparisons (GPC) method adds flexibility in defining the primary endpoint by including any number and type of outcomes that best capture the clinical benefit of a therapy as compared with standard of care. Clinically important outcomes, including bleeding severity, number of interventions, and quality of life, can easily be integrated in a single analysis. The treatment effect in GPC can be expressed by the net treatment benefit, the success odds, or the win ratio. This review provides guidance on the use of GPC and the choice of treatment effect measures for the analysis and reporting of cardiovascular trials.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37730293/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230923000906&v=2.17.9.post6+86293ac">37730293</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.047>10.1016/j.jacc.2023.06.047</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37730293</guid>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Johan Verbeeck</dc:creator>
<dc:creator>Mickaël De Backer</dc:creator>
<dc:creator>Jan Verwerft</dc:creator>
<dc:creator>Samuel Salvaggio</dc:creator>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:creator>Pascal Vranckx</dc:creator>
<dc:creator>Marc Buyse</dc:creator>
<dc:creator>Edgar Brunner</dc:creator>
<dc:date>2023-09-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Generalized Pairwise Comparisons to Assess Treatment Effects: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:37730293</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.047</dc:identifier>
</item>
<item>
<title>Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37730292/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230923000906&amp;v=2.17.9.post6+86293ac
      <description>Reducing the incidence and prevalence of standard modifiable cardiovascular risk factors (SMuRFs) is critical to tackling the global burden of coronary artery disease (CAD). However, a substantial number of individuals develop coronary atherosclerosis despite no SMuRFs. SMuRFless patients presenting with myocardial infarction have been observed to have an unexpected higher early mortality compared to their counterparts with at least 1 SMuRF. Evidence for optimal management of these patients is...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 26;82(13):1343-1359. doi: 10.1016/j.jacc.2023.06.045.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Reducing the incidence and prevalence of standard modifiable cardiovascular risk factors (SMuRFs) is critical to tackling the global burden of coronary artery disease (CAD). However, a substantial number of individuals develop coronary atherosclerosis despite no SMuRFs. SMuRFless patients presenting with myocardial infarction have been observed to have an unexpected higher early mortality compared to their counterparts with at least 1 SMuRF. Evidence for optimal management of these patients is lacking. We assembled an international, multidisciplinary team to develop an evidence-based clinical pathway for SMuRFless CAD patients. A modified Delphi method was applied. The resulting pathway confirms underlying atherosclerosis and true SMuRFless status, ensures evidence-based secondary prevention, and considers additional tests and interventions for less typical contributors. This dedicated pathway for a previously overlooked CAD population, with an accompanying registry, aims to improve outcomes through enhanced adherence to evidence-based secondary prevention and additional diagnosis of modifiable risk factors observed.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37730292/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230923000906&v=2.17.9.post6+86293ac">37730292</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.045>10.1016/j.jacc.2023.06.045</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37730292</guid>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Gemma A Figtree</dc:creator>
<dc:creator>Stephen T Vernon</dc:creator>
<dc:creator>Jason A Harmer</dc:creator>
<dc:creator>Michael P Gray</dc:creator>
<dc:creator>Clare Arnott</dc:creator>
<dc:creator>Eric Bachour</dc:creator>
<dc:creator>Giannie Barsha</dc:creator>
<dc:creator>David Brieger</dc:creator>
<dc:creator>Alex Brown</dc:creator>
<dc:creator>David S Celermajer</dc:creator>
<dc:creator>Keith M Channon</dc:creator>
<dc:creator>Nicholas W S Chew</dc:creator>
<dc:creator>James J H Chong</dc:creator>
<dc:creator>Clara K Chow</dc:creator>
<dc:creator>Peter A Cistulli</dc:creator>
<dc:creator>Patrick T Ellinor</dc:creator>
<dc:creator>Stuart M Grieve</dc:creator>
<dc:creator>Tomasz J Guzik</dc:creator>
<dc:creator>Emil Hagström</dc:creator>
<dc:creator>Alicia Jenkins</dc:creator>
<dc:creator>Garry Jennings</dc:creator>
<dc:creator>Anthony C Keech</dc:creator>
<dc:creator>Katharine A Kott</dc:creator>
<dc:creator>Leonard Kritharides</dc:creator>
<dc:creator>Mamas A Mamas</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Peter J Meikle</dc:creator>
<dc:creator>Pradeep Natarajan</dc:creator>
<dc:creator>Kazuaki Negishi</dc:creator>
<dc:creator>John O'Sullivan</dc:creator>
<dc:creator>Sanjay Patel</dc:creator>
<dc:creator>Peter J Psaltis</dc:creator>
<dc:creator>Julie Redfern</dc:creator>
<dc:creator>Philippe G Steg</dc:creator>
<dc:creator>David R Sullivan</dc:creator>
<dc:creator>Johan Sundström</dc:creator>
<dc:creator>Birgit Vogel</dc:creator>
<dc:creator>Andrew Wilson</dc:creator>
<dc:creator>Dennis Wong</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Jason C Kovacic</dc:creator>
<dc:creator>Stephen J Nicholls</dc:creator>
<dc:creator>CRE for CAD Collaborators</dc:creator>
<dc:date>2023-09-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:37730292</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.045</dc:identifier>
</item>
<item>
<title>The Burden of Chronic Medication in Congenital Heart Disease Matters</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37730291/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230923000906&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 26;82(13):1341-1342. doi: 10.1016/j.jacc.2023.07.017.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37730291/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230923000906&v=2.17.9.post6+86293ac">37730291</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.017>10.1016/j.jacc.2023.07.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37730291</guid>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Mary B Taylor</dc:creator>
<dc:date>2023-09-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Burden of Chronic Medication in Congenital Heart Disease Matters</dc:title>
<dc:identifier>pmid:37730291</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.017</dc:identifier>
</item>
<item>
<title>Chronic Medication Burden After Cardiac Surgery for Pediatric Medicaid Beneficiaries</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37730290/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230923000906&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Children who undergo cardiac surgery experience high medication burden that persists throughout childhood. Understanding chronic medication use can inform clinicians (both pediatricians and subspecialists) and policymakers, and ultimately the value of care for this medically complex population.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 26;82(13):1331-1340. doi: 10.1016/j.jacc.2023.06.046.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Congenital heart defects are the most common and resource-intensive birth defects. As children with congenital heart defects increasingly survive beyond early childhood, it is imperative to understand longitudinal disease burden.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to examine chronic outpatient prescription medication use and expenditures for New York State pediatric Medicaid enrollees, comparing children who undergo cardiac surgery (cardiac enrollees) and the general pediatric population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a retrospective cohort study of all Medicaid enrollees age &lt;18 years using the New York State Congenital Heart Surgery Collaborative for Longitudinal Outcomes and Utilization of Resources database (2006-2019). Primary outcomes were total chronic medications per person-year, enrollees per 100 person-years using ≥1 and ≥3 medications, and medication expenditures per person-year. We described and compared outcomes between cardiac enrollees and the general pediatric population. Among cardiac enrollees, multivariable regression examined associations between outcomes and clinical characteristics.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We included 5,459 unique children (32,131 person-years) who underwent cardiac surgery and 4.5 million children (22 million person-years) who did not. More than 4 in 10 children who underwent cardiac surgery used ≥1 chronic medication compared with approximately 1 in 10 children who did not have cardiac surgery. Medication expenditures were 10 times higher per person-year for cardiac compared with noncardiac enrollees. Among cardiac enrollees, disease severity was associated with chronic medication use; use was highest among infants; however, nearly one-half of adolescents used ≥1 chronic medication.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Children who undergo cardiac surgery experience high medication burden that persists throughout childhood. Understanding chronic medication use can inform clinicians (both pediatricians and subspecialists) and policymakers, and ultimately the value of care for this medically complex population.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37730290/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230923000906&v=2.17.9.post6+86293ac">37730290</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.046>10.1016/j.jacc.2023.06.046</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37730290</guid>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Joyce L Woo</dc:creator>
<dc:creator>Katherine A Nash</dc:creator>
<dc:creator>Kacie Dragan</dc:creator>
<dc:creator>Sarah Crook</dc:creator>
<dc:creator>Matthew Neidell</dc:creator>
<dc:creator>Stephen Cook</dc:creator>
<dc:creator>Edward L Hannan</dc:creator>
<dc:creator>Marshall Jacobs</dc:creator>
<dc:creator>Andrew B Goldstone</dc:creator>
<dc:creator>Christopher J Petit</dc:creator>
<dc:creator>Robert Vincent</dc:creator>
<dc:creator>Kathleen Walsh-Spoonhower</dc:creator>
<dc:creator>Ralph Mosca</dc:creator>
<dc:creator>T K Susheel Kumar</dc:creator>
<dc:creator>Neil Devejian</dc:creator>
<dc:creator>Steven A Kamenir</dc:creator>
<dc:creator>George M Alfieris</dc:creator>
<dc:creator>Michael F Swartz</dc:creator>
<dc:creator>David Meyer</dc:creator>
<dc:creator>Erin A Paul</dc:creator>
<dc:creator>Jane W Newburger</dc:creator>
<dc:creator>John Billings</dc:creator>
<dc:creator>Matthew M Davis</dc:creator>
<dc:creator>Brett R Anderson</dc:creator>
<dc:creator>New York State Congenital Heart Surgery Collaborative for Longitudinal Outcomes and Utilization of Resources (CHS-COLOUR)</dc:creator>
<dc:date>2023-09-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Chronic Medication Burden After Cardiac Surgery for Pediatric Medicaid Beneficiaries</dc:title>
<dc:identifier>pmid:37730290</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.046</dc:identifier>
</item>





























</channel>
</rss>